Navigation Links
Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
Date:3/25/2008

HOPKINTON, Mass., March 25 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the Company will host a conference call on Tuesday, April 1st, 2008 at 10:00am EDT to review 2007 Financial Results and discuss other matters related to the Company.

To access the conference call, please dial 877-718-5104 for domestic and 719-325-4843 international. The code for this conference call is 7767549. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of the website, http://www.alseres.com, within 48 hours following the conference call and will be available through Tuesday, April 15th, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE(R) which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Safe Harbor

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and Cethrin, the prospects of the Company's CNS therapeutics program, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Contact: Sharon Correia -- 508-497-2360 ext 224

Alseres Pharmaceuticals, Inc.

scorreia@alseres.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
2. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
3. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
4. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
5. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
6. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
7. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
8. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
9. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
10. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
11. Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader ... joined Biova’s Board of Directors. Dr. Henig will bring a wealth of scientific experience ... served as the Chief Technical and Scientific Officer of four major global companies in ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... the latest version of LimitLIS®, its rapidly growing Laboratory Information System. , LimitLIS® ... adoption, ensure installation integrity, and provide more customization options. Each of these has ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... Ken Hanson, ... president of Physik Instrumente USA, have been selected as this year’s recipients of two ... The two have been invited along with other honorees to accept their awards at ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... all six of their healthcare job boards. As the largest network of ... therapists, and biotechnicians, DocCafe.com and the MedJobCafe.com Health Network work to match ...
Breaking Biology Technology:
(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) is ... tech event dedicated to developing collaboration between startups and global ... June 15-17. During the event, nine startups will showcase the ... in various industries. France ... international market, with a 30 percent increase in the number ...
(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
Breaking Biology News(10 mins):